CD40
Showing 26 - 50 of 6,505
Liver Transplant Rejection Trial in Worldwide (CFZ533, Tacrolimus - MMF - corticosteroids)
Active, not recruiting
- Liver Transplant Rejection
- CFZ533
- Tacrolimus - MMF - corticosteroids
-
Los Angeles, California
- +28 more
Jan 17, 2023
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer Trial (Pegylated Liposomal Doxorubicin +
Not yet recruiting
- Platinum-resistant Ovarian Cancer
- +6 more
- Pegylated Liposomal Doxorubicin + SL-172154
- Mirvetuximab + SL-172154
- (no location specified)
Jul 29, 2022
The Effect of Human Prostate Tissue on Platelet Activation
Completed
- Prostate Hyperplasia
- +2 more
- (no location specified)
Sep 19, 2021
Epithelial Tumor, Metastatic Cancer Trial in United Kingdom, United States (NG-350A plus Pembrolizumab)
Recruiting
- Epithelial Tumor
- Metastatic Cancer
- NG-350A plus Pembrolizumab
-
Santa Monica, California
- +3 more
May 4, 2022
Non-muscle Invasive Bladder Cancer Trial in United States (2141-V11)
Recruiting
- Non-muscle Invasive Bladder Cancer
-
Basking Ridge, New Jersey
- +6 more
Dec 7, 2022
Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck Trial in United States (Drug: SL-172154)
Terminated
- Cutaneous Squamous Cell Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Drug: SL-172154
-
Los Angeles, California
- +5 more
May 18, 2022
Colorectal Tumors Trial in Portland (MEDI6469)
Terminated
- Colorectal Neoplasms
-
Portland, OregonPortland Providence Medical Center
Jan 31, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in France (Selicrelumab, Atezolizumab)
Terminated
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
-
Créteil, France
- +4 more
Jul 23, 2021
Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7 Trial in
Recruiting
- Metastatic Colorectal Adenocarcinoma
- +5 more
- Imiquimod
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Aug 26, 2022
Metastatic Pancreatic Ductal Adenocarcinoma Trial in Belgium, France, Spain (CD40 agonist mitazalimab in combination with chemo)
Recruiting
- Metastatic Pancreatic Ductal Adenocarcinoma
- CD40 agonist mitazalimab in combination with chemotherapy
-
Brussels, Belgium
- +15 more
Aug 12, 2022
Acute Myeloid Leukemia, MDS Trial in United States (SL-172154)
Recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
-
Duarte, California
- +12 more
Jan 23, 2023
Unresectable Melanoma, Metastatic Melanoma Trial in Poland, Spain (APX005M)
Active, not recruiting
- Unresectable Melanoma
- Metastatic Melanoma
-
Warsaw, Poland
- +12 more
Mar 8, 2022
Locally Advanced Rectal Adenocarcinoma Trial in United States (APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days, mFOLFOX and
Recruiting
- Locally Advanced Rectal Adenocarcinoma
- APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days
- mFOLFOX and Radiation Therapy 5Gy x 5 days
-
Winston-Salem, North Carolina
- +2 more
Sep 14, 2021
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody
Active, not recruiting
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Anti-OX40 Agonist Monoclonal Antibody PF-04518600
- +6 more
-
Houston, TexasM D Anderson Cancer Center
Jan 25, 2022
Relapsed/Refractory Trial in Santa Fe (Tafasitamab, Lenalidomide, Tazemetostat)
Recruiting
- Relapsed/Refractory
- Tafasitamab
- +8 more
-
Santa Fe, CaliforniaCalifornia Cancer Associates For Research And Excellence, cCARE
Feb 23, 2022
Kidney Transplant Rejection Trial in Worldwide (CFZ533 - MMF - CS, Tacrolimus - MMF - +/- corticosteroids)
Completed
- Kidney Transplant Rejection
- CFZ533 - MMF - CS
- Tacrolimus - MMF - +/- corticosteroids
-
Los Angeles, California
- +73 more
Jun 8, 2022
